Andrew M Bellinger

Plain English
This study looked at a new treatment called VERVE-101, which uses a technique called CRISPR to permanently change DNA in order to reduce "bad" cholesterol levels. In experiments with monkeys, the treatment was found to lower a protein linked to cholesterol by 83% and the cholesterol levels themselves by 69% after about 476 days. The treatment was safe, showing only temporary mild side effects, and it did not affect reproductive cells in a way that would pass changes to future generations. Who this helps: This benefits patients with high cholesterol, especially those with genetic conditions like familial hypercholesterolemia.

Plain English
This study focused on a new way to deliver a CRISPR therapy to the liver using special nanoparticles that don't rely on a common receptor that some patients lack. The researchers found that by modifying these nanoparticles, they could increase liver editing from 5% to 61% in certain monkeys, and this treatment led to a significant decrease in a specific protein related to cholesterol levels, achieving reductions of up to 89% six months later. This matters because it provides a potential treatment option for patients who cannot use traditional methods due to their genetic conditions. Who this helps: Patients with homozygous familial hypercholesterolemia and other liver-related disorders.

Plain English
The study examined how to improve the accuracy of guide RNA used in CRISPR gene editing. Researchers found a way to detect and measure tiny impurities in the RNA, achieving precision down to less than 1%. This matters because ensuring the guide RNA is correct can enhance the effectiveness and safety of CRISPR-based treatments for genetic disorders. Who this helps: This benefits patients with genetic diseases who may receive CRISPR therapies.

Plain English
Researchers used a gene-editing tool called CRISPR to permanently disable a gene in monkeys' livers that controls cholesterol production, delivering it through tiny fat particles injected into the bloodstream. After a single injection, the monkeys' cholesterol dropped by about 60% and stayed low for at least 8 months without any additional treatment. This proves that gene editing could offer heart disease patients a one-time treatment instead of taking cholesterol drugs for life.

Plain English
Researchers developed a new drug delivery system that can stay in the stomach and release large doses of antibiotics over several weeks to treat tuberculosis (TB), which usually requires long-term daily medication. In tests with pigs, this system showed it could safely hold and release several grams of TB antibiotics. This is important because it can make it easier for patients to stick to their treatment plans, improving their chances of recovery. Who this helps: This helps patients with tuberculosis who need long-term antibiotic treatment.

Plain English
This study looked at a new way to deliver a medication called memantine for Alzheimer's disease that only needs to be taken once a week. The researchers found that their new pill could stay in the stomach and release the medication over seven days, providing consistent levels in the bloodstream that are similar to taking seven daily pills. This is important because it could help improve how well patients stick to their medication schedules, which is a common problem in treating dementia. Who this helps: This benefits patients with Alzheimer's disease and their caregivers.

Plain English
Researchers worked on creating a new type of oral medication for HIV that only needs to be taken once a week, instead of every day. They found that their new drug system kept effective levels of HIV-fighting medications in the body for a week in pigs. This approach could greatly help people stick to their treatment, potentially reducing the number of new HIV cases by hundreds of thousands. Who this helps: This benefits patients with HIV by making treatment easier and more effective.

Plain English
This study looked at new types of pills that can stay in the stomach and release medicine over a longer time—up to a week or longer. Most current options only work for less than one day, but researchers are creating designs that can help with this issue. These long-lasting pills could make it much easier for patients to manage chronic illnesses by reducing how often they need to take their medication. Who this helps: This helps patients with chronic conditions who need to take medication regularly.

Plain English
Researchers created a new type of oral capsule that slowly releases a drug called ivermectin over two weeks to help control malaria. In tests with pigs, this capsule worked well without causing any harm to their digestive systems. This breakthrough could significantly improve efforts to eliminate malaria, especially in rural areas where getting treatment to people is challenging. Who this helps: Patients in areas affected by malaria.

Plain English
This study looked at a special type of gel made for devices that stay in the stomach, helping with tasks like monitoring health and delivering medicines. Researchers found that this gel is stretchy and safe in the stomach but dissolves in the intestines, reducing the risk of blockages if a device breaks. In tests with large animals, these devices stayed in the stomach longer and passed through safely, making them a safer option for patients. Who this helps: This helps patients using gastric devices and their doctors.

Plain English
This study looked at how new cancer treatments, especially targeted therapies that focus on specific cell processes, can impact heart health. Researchers found that while these therapies can effectively treat cancer, they might also cause heart problems. The collaboration between heart doctors and cancer specialists is crucial, as it allows for a better understanding of how these treatments can both harm and help heart health. Who this helps: This benefits cancer patients who may face heart risks from their treatments.

Plain English
The study looked at a specific issue in Duchenne muscular dystrophy (DMD), a condition that causes muscle weakness due to a lack of a protein called dystrophin. Researchers found that in mice with DMD, a calcium-releasing channel in muscle cells became "leaky" due to a chemical change called S-nitrosylation, which led to more muscle damage and weakness. By using a compound called S107 to prevent this leakage, they improved muscle function and exercise performance in the mice, suggesting a new potential treatment for DMD. Who this helps: This helps patients with Duchenne muscular dystrophy by offering insights for new treatment options.

Plain English
This study looked at how stress affects the way muscles work by focusing on a specific protein called the ryanodine receptor, which helps release calcium in muscle cells. Researchers found that stress can disrupt the normal function of this receptor, leading to muscle fatigue and weakness. Understanding these changes is important because it could pave the way for better treatments for conditions like heart failure and muscular disorders. Who this helps: This helps patients with muscular disorders and heart conditions.

Plain English
This study examined how changes to a crucial calcium release channel in muscles, called the ryanodine receptor (RyR1), affect exercise performance. Researchers found that in both mice and humans, exercise can cause this channel to leak calcium, making it less effective, which leads to poorer exercise ability. For example, mice without a stabilizing protein called calstabin1 showed a significant drop in exercise capacity, indicating that fixing the leaking channels can boost muscle performance. Who this helps: This research helps patients with muscle disorders and doctors treating them.

Plain English
This study looked at how mice that can't generate heat through a specific protein (UCP1) cope with cold temperatures. It found that these mice rely solely on shivering, which leads to serious problems in their muscle function, showing a 50% decrease in calcium release necessary for muscle contractions, while other non-shivering muscles were less affected. This is important because it shows that the ability to generate heat without shivering protects muscles during cold exposure, highlighting potential benefits for muscle health in cold environments. Who this helps: This helps patients with muscle disorders and doctors working on treatments related to muscle function in cold conditions.

Plain English
This study investigated how a protein called protein kinase G (PKG) affects calcium channels in heart cells, specifically focusing on two parts of the calcium channel known as Cav1.2 alpha1c and beta2 subunits. The researchers found that PKG attaches to specific sites on these subunits and, when active, reduces the overall calcium flow through the channel. This reduction in calcium flow is important because it helps control heart contractions, which affects how well the heart functions. Who this helps: This benefits patients with heart conditions by improving our understanding of how heart muscle contractions are regulated.

Plain English
This paper looks at how the harmful effects of lead exposure on children were long ignored in U.S. policy, even after it was clear that lead could seriously harm health. For example, lead was found in many products like paint and gasoline, despite evidence linking it to significant health issues, particularly affecting disadvantaged families. This slow response highlights how societal attitudes and competing priorities can delay important health measures. Who this helps: This helps children from low-income families who are most at risk for lead poisoning.